A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function
NCT01631097 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44
Last updated 2014-01-27
Summary
This Phase 1, open-label, single dose study is designed to evaluate the pharmacokinetics, safety and tolerability of a single 1.5 mg tivozanib dose in subjects with varying degrees of hepatic impairment and normal hepatic function.
Conditions
- Hepatic Impairment
Interventions
- DRUG
-
Tivozanib hydrochloride
Single oral capsule 1.5 mg tivozanib hydrochloride
Sponsors & Collaborators
-
AVEO Pharmaceuticals, Inc.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2012-05-31
- Primary Completion
- 2014-01-31
- Completion
- 2014-01-31
Countries
- United States
Study Locations
More Related Trials
-
A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)
NCT01767688 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
NCT06858696 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants
NCT07198087 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment
NCT02581592 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluate Severe Hepatic Impairment on Dacomitinib PK
NCT03865446 ·Status: COMPLETED ·Phase: PHASE1
-
KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment
NCT04166942 ·Status: COMPLETED ·Phase: PHASE1
-
Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function
NCT00831532 ·Status: COMPLETED ·Phase: PHASE1
-
The Study to Assess the Pharmacokinetics of Pimicotinib in Subjects With Mild and Moderate Hepatic Impairment Relative to Subjects With Normal Hepatic Function
NCT06562946 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)
NCT02421042 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment
NCT02873650 ·Status: TERMINATED ·Phase: PHASE1
-
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
NCT06952634 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants
NCT07250633 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls
NCT07018492 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib
NCT04772612 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects
NCT03681457 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function
NCT03902002 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function
NCT05610657 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment
NCT04587622 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function
NCT02524717 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine
NCT05935033 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants
NCT05490030 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment
NCT03983161 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of TAK-279 in Adults With or Without Liver Damage
NCT05976321 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment
NCT04887064 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects
NCT02857868 ·Status: COMPLETED ·Phase: PHASE1